Literature DB >> 19694224

Yin and yang of the plasminogen activator inhibitor.

Jerzy Jankun1, Ewa Skrzypczak-Jankun.   

Abstract

Plasminogen activator inhibitor type one (PAI-1) is involved in many biological processes, and depending on a disease its overexpression, deficiency or normal level can sometimes produce surprising outcomes. This paper reviews low, high, and normal levels of PAI-1 in relation to diseases, their incidents, and possible treatment. Also, a role of PAI-1 in cancer is discussed with attention to "PAI-1 paradox" and explanation of the possible therapeutic applications using this protein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19694224

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  10 in total

1.  Aging and Cardiac Fibrosis.

Authors:  Anna Biernacka; Nikolaos G Frangogiannis
Journal:  Aging Dis       Date:  2011-04       Impact factor: 6.745

2.  Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1.

Authors:  Jerzy Jankun; Ewa Skrzypczak-Jankun
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

3.  Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.

Authors:  Daniel Glenn Kindell; Rick Wayne Keck; Jerzy Jankun
Journal:  Exp Ther Med       Date:  2015-04-01       Impact factor: 2.447

4.  NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect.

Authors:  Georgios C Stefos; Ulf Soppa; Mara Dierssen; Walter Becker
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

Review 5.  Predictive Role of Coagulation, Fibrinolytic, and Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review.

Authors:  Alexander Weymann; Anton Sabashnikov; Sadeq Ali-Hasan-Al-Saegh; Aron-Frederik Popov; Seyed Jalil Mirhosseini; William L Baker; Mohammadreza Lotfaliani; Tong Liu; Hamidreza Dehghan; Senol Yavuz; Michel Pompeu Barros de Oliveira Sá; Jae-Sik Jang; Mohamed Zeriouh; Lei Meng; Fabrizio D'Ascenzo; Abhishek J Deshmukh; Guiseppe Biondi-Zoccai; Pascal M Dohmen; Hugh Calkins; Integrated Meta-Analysis Of Cardiac Cardiac Surgery And Cardiology-Group Imcsc-Group
Journal:  Med Sci Monit Basic Res       Date:  2017-03-31

Review 6.  Can components of the plasminogen activation system predict the outcome of kidney transplants?

Authors:  Jerzy Jankun; Omar A Khan; Hesham I Mostafa; Puneet Sindhwani; Ewa Skrzypczak-Jankun
Journal:  Cent Eur J Immunol       Date:  2018-06-30       Impact factor: 2.085

Review 7.  Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).

Authors:  Marzena Wyganowska-Świątkowska; Mateusz Tarnowski; Daniel Murtagh; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

8.  Synergistic anticancer activity of biologicals from green and black tea on DU 145 human prostate cancer cells.

Authors:  Andrew J Kobalka; Rick W Keck; Jerzy Jankun
Journal:  Cent Eur J Immunol       Date:  2015-04-22       Impact factor: 2.085

9.  Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivatives.

Authors:  Shireen Parsai; Rick Keck; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Oncol Lett       Date:  2013-11-12       Impact factor: 2.967

Review 10.  Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

Authors:  Marzena Wyganowska-Świątkowska; Maja Matthews-Kozanecka; Teresa Matthews-Brzozowska; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.